BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25199680)

  • 21. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
    Yeo W; Chan PK; Ho WM; Zee B; Lam KC; Lei KI; Chan AT; Mok TS; Lee JJ; Leung TW; Zhong S; Johnson PJ
    J Clin Oncol; 2004 Mar; 22(5):927-34. PubMed ID: 14990649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
    Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
    Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
    J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
    Kim JS; Hahn JS; Park SY; Kim Y; Park IH; Lee CK; Cheong JW; Lee ST; Min YH
    Yonsei Med J; 2007 Feb; 48(1):78-89. PubMed ID: 17326249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
    Rossi G; Pelizzari A; Motta M; Puoti M
    Br J Haematol; 2001 Oct; 115(1):58-62. PubMed ID: 11722410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.
    Cil T; Altintas A; Pasa S; Bayan K; Ozekinci T; Isikdogan A
    Leuk Lymphoma; 2008 May; 49(5):939-47. PubMed ID: 18464113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis.
    Tang W; Chen L; Zheng R; Pan L; Gao J; Ye X; Zhang X; Zheng W
    PLoS One; 2015; 10(6):e0128673. PubMed ID: 26057738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.
    Hsu C; Hsiung CA; Su IJ; Hwang WS; Wang MC; Lin SF; Lin TH; Hsiao HH; Young JH; Chang MC; Liao YM; Li CC; Wu HB; Tien HF; Chao TY; Liu TW; Cheng AL; Chen PJ
    Hepatology; 2008 Mar; 47(3):844-53. PubMed ID: 18302293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
    Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
    Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
    Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
    J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
    Li YH; He YF; Jiang WQ; Wang FH; Lin XB; Zhang L; Xia ZJ; Sun XF; Huang HQ; Lin TY; He YJ; Guan ZZ
    Cancer; 2006 Mar; 106(6):1320-5. PubMed ID: 16470607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis.
    Xu Z; Dai W; Wu YT; Arshad B; Li X; Wu H; Chen HR; Wu KN; Kong LQ
    Eur J Cancer Care (Engl); 2018 Mar; 27(2):e12799. PubMed ID: 29265535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal.
    Cerva C; Maffongelli G; Svicher V; Salpini R; Colagrossi L; Battisti A; Mariotti B; Cerretti R; Cudillo L; Sarmati L
    BMC Infect Dis; 2017 Aug; 17(1):566. PubMed ID: 28806922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy.
    Rossi G
    Leuk Lymphoma; 2003 May; 44(5):759-66. PubMed ID: 12802911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.
    Idilman R; Arat M; Soydan E; Törüner M; Soykan I; Akbulut H; Arslan O; Ozcan M; Türkyilmaz AR; Bozdayi M; Karayalçin S; Van Thiel DH; Ozden A; Beksaç M; Akan H
    J Viral Hepat; 2004 Mar; 11(2):141-7. PubMed ID: 14996349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.
    Wu YT; Li X; Liu ZL; Xu Z; Dai W; Zhang K; Wu JS; Arshad B; Wu KN; Kong LQ
    PLoS One; 2017; 12(6):e0179680. PubMed ID: 28640902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
    An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lamivudine therapy in acute leukemia patients who are hepatitis B surface antigen carriers.
    Yilmaz M; Dagdas S; Güler N; Aki SZ; Aköz AG; Özet G; Ayli M; Saritas U
    Hematology; 2003 Dec; 8(6):393-6. PubMed ID: 14668034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.
    Lee GW; Ryu MH; Lee JL; Oh S; Kim E; Lee JH; Kim SB; Kim SW; Suh C; Lee KH; Kim WK; Lee JS; Kang YK
    J Korean Med Sci; 2003 Dec; 18(6):849-54. PubMed ID: 14676442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.